The committee convened to discuss tofersen, an experimental injection for treatment of ALS.

Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.

Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.

Medicare should require safety monitoring and medical expertise in the use of aducanumab.

While we might not have clear progress, we do have an advance.

It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.